Recent

% | $
Quotes you view appear here for quick access.

MasterCard Incorporated Message Board

  • aunttizzy aunttizzy Oct 25, 2012 1:34 PM Flag

    Something To Consider

    The announcement that Mannkind has issued a new secondary to raise funds has created a buying opportunity.

    Mannkind's insulin drug, Afrezza, could receive F.D.A. approval as early as September,2013 if it is granted "priority review" status.

    With $1.6 billion in tax-loss carry forwards and insulin inventory to produce $10,000,000,000 worth of Afrezza the company in a potential takeover target which may be why Mr. Mann probably decided to convert so much debt to equity at $2.59/share last week.

    A "big-pharma" partnership could happen at any time.

    Consider buying a few shares below $2.00 before the approval run-up begins.

 
MA
95.59+0.06(+0.06%)Aug 25 4:01 PMEDT